Login to Your Account


Friday, July 25, 2014
Gilead Sciences Inc., of Foster City, Calif., saw shares (NASDAQ:GILD) trading flat Thursday despite Wednesday's post-close report that sales of the company's hepatitis C treatment Sovaldi (sofosbuvir) hit nearly $3.5 billion for the second quarter, swelling its net profit to about $3.66 billion, or $2.20 per share, up from $772.6 million, or 46 cents per share, a year ago.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription